This article is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Never start, stop, or change medication without consulting your prescribing physician. Every person responds differently to medication.
What people describe
As stimulant medication wears off, many people experience some combination of: irritability, emotional sensitivity, fatigue, difficulty concentrating (worse than baseline), restlessness, sadness, or a general "flatness." This is commonly called the "crash," "rebound," or "comedown" — and it's one of the most discussed aspects of ADHD medication treatment.
The experience varies significantly by medication type, dose, individual, and day. Not everyone experiences it, and for those who do, severity ranges from barely noticeable to significantly impairing.
The pharmacology behind it
When stimulant medication is active, it increases dopamine and norepinephrine availability in the synaptic cleft. As the medication is metabolized and cleared from the body, neurotransmitter levels return toward baseline — but they may temporarily dip below pre-medication levels before stabilizing.
This is called rebound, and it's a recognized pharmacological phenomenon. Carlson & Kelly (2003) documented rebound effects in children on methylphenidate, observing 149 hospitalized children who mostly took short-acting methylphenidate. About 30% showed rebound after at least one dose, though fewer than 10% had rebound severe enough to matter clinically.
The speed of the drop matters. Immediate-release formulations (like Adderall IR) produce a sharper transition because the medication clears more abruptly. Extended-release formulations and prodrugs like Vyvanse generally produce a more gradual decline, which many people find more tolerable.
The emotional component of the crash — the irritability, sadness, or emotional flooding — may relate to dopamine's role in emotional regulation. When dopamine dips, the prefrontal cortex's ability to modulate emotional responses temporarily decreases, making you more reactive to frustration, criticism, or even neutral events.
Strategies with evidence
- Timing awareness: Know approximately when your medication wears off and plan accordingly. Avoid scheduling emotionally demanding conversations or high-stakes decisions for this window.
- Protein and complex carbs: Eating during the transition may help stabilize blood sugar and provide amino acid precursors for dopamine production. See medication and food.
- Low-demand bridge activities: Some people benefit from having a "decompression" activity planned for the transition: a walk, music, stretching, or time outside. The goal is to lower demands during the neurochemical dip.
- Exercise: Physical activity during or just before the wear-off window may help. Pontifex et al. (2013) showed that acute exercise improves executive function in ADHD. A 20-minute walk may partially buffer the transition.
- Booster doses: For IR formulations, a low-dose afternoon booster — prescribed by your doctor — can extend coverage and soften the transition. This is common clinical practice.
- Formulation changes: If the crash is severe and consistent, your prescriber may recommend switching to a longer-acting formulation or a prodrug with a smoother pharmacokinetic curve.
When the "crash" might be something else
Sometimes what feels like a medication crash is actually:
- Skipped meals — appetite suppression during the day followed by blood sugar crash in the evening
- Dehydration — stimulants can reduce thirst awareness
- Accumulated fatigue — medication can mask tiredness during the day; when it wears off, the accumulated deficit hits
- Returning baseline ADHD — this isn't a "crash," it's just your unmedicated experience, which may feel worse by contrast
Tracking your daily patterns — including food, water, sleep, and mood at different times — can help distinguish these. UpOrbit's wellness check-ins are designed for exactly this kind of pattern recognition.
References
- Carlson & Kelly (2003). Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol, 13(2), 137-142.
- Pontifex et al. (2013). Exercise and attention in ADHD. J Pediatrics, 162(3).